| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 4 | +50.00% | -5.90% | -0.96% | -4.94% | -3.26% | — |
| 14d | 4 | +50.00% | -6.31% | -0.61% | -5.69% | -1.96% | — |
| 30d | 4 | +25.00% | +4.75% | -1.54% | +6.29% | +7.18% | — |
| 60d | 4 | +75.00% | -3.65% | -3.38% | -0.27% | -4.53% | — |
| 90d | 4 | +75.00% | -8.76% | -1.15% | -6.51% | -15.44% | — |
| 180d | 4(3 pending) | +0.00% | +10.69% | +5.98% | +4.71% | +4.71% | — |
| 1y | 4(4 pending) | — | — | — | — | — | — |
| 2y | 4(4 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| CTNM CONTINEUM THERAPEUTICS, INC. | PURCHASE CMO & Head of Development | 10,833 | $4.50 | $48.7K | 19,794 | Jun 30, 2026 | Jul 1, 2026 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 10,833 | $16.02 | $173.6K | 8,961 | Jun 30, 2026 | Jul 1, 2026 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | SALE CMO & Head of Development | 10,833 | — | — | 238,334 | Jun 30, 2026 | Jul 1, 2026 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | SALE CMO & Head of Development | 3,611 | — | — | 249,167 | Mar 2, 2026 | Mar 2, 2026 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 3,611 | $15.02 | $54.2K | 0 | Mar 2, 2026 | Mar 2, 2026 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | PURCHASE CMO & Head of Development | 3,611 | $4.50 | $16.2K | 3,611 | Mar 2, 2026 | Mar 2, 2026 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 160,000 | — | — | 160,000 | Jan 30, 2026 | Jan 30, 2026 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | PURCHASE CMO & Head of Development | 3,611 | $4.50 | $16.2K | 3,611 | Jan 28, 2026 | Jan 30, 2026 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 2,800 | $14.09 | $39.4K | 811 | Jan 28, 2026 | Jan 30, 2026 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | SALE CMO & Head of Development | 3,611 | — | — | 252,778 | Jan 28, 2026 | Jan 30, 2026 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 811 | $14.48 | $11.7K | 0 | Jan 28, 2026 | Jan 30, 2026 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | PURCHASE CMO & Head of Development | 3,611 | $4.50 | $16.2K | 3,611 | Dec 29, 2025 | Dec 30, 2025 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | SALE CMO & Head of Development | 3,611 | — | — | 256,389 | Dec 29, 2025 | Dec 30, 2025 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 3,611 | $12.06 | $43.6K | 0 | Dec 29, 2025 | Dec 30, 2025 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 260,000 | — | — | 260,000 | Apr 28, 2025 | Apr 28, 2025 ↗ | View → |
| CTNM CONTINEUM THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 26,000 | — | — | 26,000 | Apr 28, 2025 | Apr 28, 2025 ↗ | View → |